Dossier Development

NextPharma is developing its own dossiers for which it licenses the sales, marketing and distribution rights to customers. NextPharma its network of manufacturing sites to manufacture the products commercially providing simplicity and convenience to customers.

The following products have been approved within Europe:

20 µg Ethinylestradiol and 100 µg Levonorgestrel combination
30 µg Ethinylestradiol and 150 µg Levonorgestrel combination

The following products have been filed within Europe:

20µg Ethinylestradiol and 75 µg Gestodene combination